Non-Invasive Fetal Blood Group Genotyping: Moving Towards Precision Care for Pregnant Individuals in Ontario

Advances in prenatal testing are transforming how we care for pregnant patients, enabling more precise, personalized care while reducing unnecessary interventions. As Ontario implements non-invasive fetal blood group genotyping, healthcare providers have an important opportunity to understand how these new tests will improve clinical decision-making and patient outcomes. This webinar provides an overview of Ontario’s upcoming implementation of non-invasive fetal blood group genotyping, including the Fetal RHD Screen and the Alloimmunized Fetal Blood Group Genotyping test. Participants will learn the clinical significance of these tests, when and how to order them, and how they support more precise prenatal care by reducing unnecessary Rh Immune Globulin administration and streamlining the management of pregnancies affected by red blood cell alloimmunization. The session will also explore workflow integration, clinical scenarios and the provider and patient resources available to support implementation.

Presented by

• Joshua Stern, MD
  Family Medicine Advisor, Prenatal Screening Ontario

• Vicky Ward, BScN, MScN
  Clinical Content Specialist, Prenatal Screening Ontario, part of BORN Ontario at CHEO

Learning objectives

1. Explain the clinical significance of the new non-invasive fetal blood group genotyping tests and how implementation will enhance and influence current practice.
2. Describe when to order fetal blood group genotyping and understand how precision medicine can help guide more targeted and equitable access to pregnancy care.
3. Identify reliable sources for additional information, guidance, and clinical resources related to the new non-invasive fetal blood group genotyping tests.

Registration

Register for the event here.

For more information about BORN and other webinars, please visit their website.